Background & Aims
Abbreviations used in this paper:ATI (antibodies to infliximab), CI (confidence interval), CRP (C-reactive protein), HR (hazard ratio), IBD (inflammatory bowel disease), IFX (infliximab), IMM (immunomodulator), IR (infusion reaction), IV (intravenous), LOR (loss of response), ROC (receiver operating curve), TL (trough level), TNF (tumor necrosis factor)
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Anti-TNF therapy in inflammatory bowel diseases: a huge review.Minerva Gastroenterol Dietol. 2010; 56: 233-243
- Intensification of infliximab therapy in Crohn's disease: efficacy and safety.J Crohns Colitis. 2012; 6: 62-67
- Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review.Am J Gastroenterol. 2011; 106: 674-684
- Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients.J Crohns Colitis. 2013; 7: 154-160
- Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review.Am J Gastroenterol. 2009; 104: 760-767
- Review article: causative factors and the clinical management of patients with Crohn's disease who lose response to anti-TNF therapy.Aliment Pharmacol Ther. 2011; 34: 1-10
- Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.N Engl J Med. 2003; 348: 601-608
- Immunogenicity of infliximab: how to handle the problem?.Acta Gastroenterol Belg. 2007; 70: 163-170
- Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum.J Immunol Methods. 2012; 382: 177-188
- Antibody response to infliximab and its impact on pharmacokinetics can be transient.Am J Gastroenterol. 2013; 108: 962-971
- Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays.Aliment Pharmacol Ther. 2012; 36: 765-771
- Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease.Gastroenterology. 2003; 124: 917-924
- Comparison of techniques for monitoring infliximab bioavailability and immunogenicity in Crohn's disease.Gastroenterology. 2012; 142 (S-781)
- Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis.Gut. 2010; 59: 49-54
- Early serial trough and antidrug antibody level measurements predict clinical outcome of infliximab and adalimumab treatment.Gut. 2012; 61: 321
- Can clinical, biological or pharmacological markers predict sustained response to infliximab? A retrospective analysis of ACCENT 1.Gut. 2011; 60: A296
- Importance of trough levels and antibodies on the long term treatment efficacy of infliximab therapy in ulcerative colitis.J Crohn Colitis. 2012; 6: S5
- Certolizumab pegol plasma concentrations and endoscopic response and remission in Crohn's disease.Gut. 2012; 61: A81
- Benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials.Aliment Pharmacol Ther. 2009; 30: 210-226
- Infliximab trough levels and CRP during infliximab-immunomodulator combination treatment for Crohn's disease are associated with clinical outcome after immunomodulator withdrawal.Gastroenterology. 2011; 140 (S-279)
- The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab.Gut. 2014; 63: 1258-1264
- Addition of an immunomodulator to infliximab therapy eliminates anti-drug antibodies in serum and restores clinical response of patients with inflammatory bowel disease.Clin Gastroenterol Hepatol. 2013; 11: 444-447
- Anti-TNF monoclonal antibodies in IBD: pharmacokinetics-based dosing paradigms.Clin Pharmacol Ther. 2012; 91: 635-646
- OP11 Individualised infliximab treatment using therapeutic drug monitoring: A prospective controlled Trough level Adapted infliXImab treatment (TAXIT) trial.J Crohns Colitis. 2012; 6 (S-6)
This article has an accompanying continuing medical education activity on page e91. Learning Objectives—At the end of this activity, the successful learner will be able to identify clinical and biological factors predictive of safe and successful restarting of infliximab after a drug holiday. This will translate in a safe and more effective (re)start of infliximab, especially in patients at high risk.
Conflicts of interest The authors disclose the following: Filip Baert has received research grants from Abbott and MSD, and speaker and consultancy fees from Abbott, MSD, Falk, Pfizer, and Vifor. David Drobne has received lecture and consultancy fees from MSD, Abbott, and Pfizer. Ann Gils has received speakers fees from Pfizer and MSD. Niels Vande Casteele has received consultancy fees from MSD and Janssen Biologics. Scott Hauenstein, Sharat Singh, and Steve Lockton are employees of Prometheus Laboratories, Inc. Paul Rutgeerts has received financial support for research from UCB Pharma, Abbvie, Janssen Biologics, Merck, and Prometheus, lecture fees from Abbvie and Merck, and consultancy fees Amgen, Merck, UCB Pharma, Genentech, BMS, Abbvie, Janssen Biologics, Millenium, Neovacs, Actogenics, and Prometheus. Séverine Vermeire has received research grants from Centocor, MSD, Abbott, and UCB, has received speakers fees and/or consultancy fees from Centocor, MSD, Abbott, UCB, Pfizer, Ferring, and Shire.
Funding Niels Vande Casteele is a postdoctoral fellow of the Research Foundation–Flanders, Belgium. Séverine Vermeire is a Senior Clinical Investigator from the Funds for Scientific Research Flanders.